Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes: the TRIGR nested case-control ancillary study

Maija E Miettinen, Sari Niinistö, Iris Erlund, David Cuthbertson, Anita M Nucci, Jarno Honkanen, Outi Vaarala, Heikki Hyöty, Jeffrey P Krischer, Mikael Knip, Suvi M Virtanen, TRIGR Investigators, Maija E Miettinen, Sari Niinistö, Iris Erlund, David Cuthbertson, Anita M Nucci, Jarno Honkanen, Outi Vaarala, Heikki Hyöty, Jeffrey P Krischer, Mikael Knip, Suvi M Virtanen, TRIGR Investigators

Abstract

Aims/hypothesis: Our aim was to study the association between serum 25-hydroxyvitamin D (25OHD) concentration and islet autoimmunity and type 1 diabetes in children with an increased genetic risk of type 1 diabetes.

Methods: Serum samples for 25OHD measurements were obtained in the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) ancillary study (Divia) from children in 15 countries. Case children (n = 244) were defined as having positivity for at least two out of four diabetes-associated autoantibodies measured at any one sample. For each case child, two control children were selected matched for country and date of birth (±1 year) (n = 488). Of the case children, 144 developed type 1 diabetes. Serum 25OHD was measured repeatedly in infancy and childhood and was compared according to age at the first seroconversion (at 6, 12 and 18 months prior to and at seroconversion) and calendar age (0, 6, 12 and 18 months).

Results: In children with islet autoimmunity, mean serum 25OHD concentration was lower 18 months prior to the age of first seroconversion of the case children compared with the control children (57.7 vs 64.8 nmol/l, p = 0.007). In children with type 1 diabetes (n = 144), mean serum 25OHD concentration was lower 18 months prior to the age of the first seroconversion (58.0 vs 65.0 nmol/l, p = 0.018) and at the calendar age of 12 months (70.1 vs 75.9 nmol/l, p = 0.031) than in their control counterparts. Analyses were adjusted for month of sample collection, human leucocyte antigen genotype, maternal type 1 diabetes and sex.

Conclusions/interpretation: The results suggest that early postnatal vitamin D may confer protection against the development of type 1 diabetes.

Trial registration: ClinicalTrials.gov NCT00179777.

Keywords: 25-Hydroxyvitamin D; Islet autoimmunity; Type 1 diabetes; Vitamin D.

References

    1. Knip M, Korhonen S, Kulmala P, et al. Prediction of type 1 diabetes in the general population. Diabetes Care. 2010;33:1206–1212. doi: 10.2337/dc09-1040.
    1. Mäkinen M, Mykkänen J, Koskinen M, et al. Serum 25-hydroxyvitamin D concentrations in children progressing to autoimmunity and clinical type 1 diabetes. J Clin Endocrinol Metab. 2016;101(2):723–729. doi: 10.1210/jc.2015-3504.
    1. Mäkinen M, Löyttyniemi E, Koskinen M, et al. Serum 25-hydroxyvitamin D concentrations at birth in children screened for HLA-DQB1 conferred risk for type 1 diabetes. J Clin Endocrinol Metab. 2019;104(6):2277–2285. doi: 10.1210/jc.2018-02094.
    1. Simpson M, Brady H, Yin X, et al. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY) Diabetologia. 2011;54(11):2779–2788. doi: 10.1007/s00125-011-2278-2.
    1. Norris JM, Lee HS, Frederiksen B, et al. Plasma 25-hydroxyvitamin D concentration and risk of islet autoimmunity. Diabetes. 2018;67(1):146–154. doi: 10.2337/db17-0802.
    1. Sørensen IM, Joner G, Jenum PA, Eskild A, Torjesen PA, Stene LC. Maternal serum levels of 25-hydroxy-vitamin D during pregnancy and risk of type 1 diabetes in the offspring. Diabetes. 2012;61:175–178. doi: 10.2337/db11-0875.
    1. Miettinen ME, Reinert L, Kinnunen L, et al. Serum 25-hydroxyvitamin D level during early pregnancy and type 1 diabetes risk in the offspring. Diabetologia. 2012;55:1291–1294. doi: 10.1007/s00125-012-2458-8.
    1. Thorsen SU, Mårild K, Olsen SF, et al. Lack of association between maternal or neonatal vitamin D status and risk of childhood type 1 diabetes: a Scandinavian case-cohort study. Am J Epidemiol. 2018;187(6):1174–1181. doi: 10.1093/aje/kwx361.
    1. Jacobsen R, Thorsen SU, Cohen AS, et al. Neonatal vitamin D status is not associated with later risk of type 1 diabetes: results from two large Danish population-based studies. Diabetologia. 2016;59(9):1871–1881. doi: 10.1007/s00125-016-4002-8.
    1. Dong JY, Zhang WG, Chen JJ, Zhang ZL, Han SF, Qin LQ. Vitamin D intake and risk of type 1 diabetes: a meta-analysis of observational studies. Nutrients. 2013;5(9):3551–3562. doi: 10.3390/nu5093551.
    1. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358:1500–1503. doi: 10.1016/S0140-6736(01)06580-1.
    1. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016;387(10035):2331–2339. doi: 10.1016/S0140-6736(16)30582-7.
    1. Tapia G, Mårild K, Dahl SR, et al. Maternal and newborn vitamin D-binding protein, vitamin D levels, vitamin D receptor genotype, and childhood type 1 diabetes. Diabetes Care. 2019;42(4):553–559. doi: 10.2337/dc18-2176.
    1. Saccone D, Asani F, Bornman L. Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. Gene. 2015;561(2):171–180. doi: 10.1016/j.gene.2015.02.024.
    1. Knip M, Luopajärvi K, Härkönen T. Early life origin of type 1 diabetes. Semin Immunopathol. 2017;39(6):653–667. doi: 10.1007/s00281-017-0665-6.
    1. Knip M, Åkerblom HK, Becker D, et al. Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. JAMA. 2014;311(22):2279–2287. doi: 10.1001/jama.2014.5610.
    1. Cashman KD, Dowling KG, Škrabáková Z, et al. Standardizing serum 25-hydroxyvitamin D data from four Nordic population samples using the Vitamin D Standardization Program protocols: shedding new light on vitamin D status in Nordic individuals. Scand J Clin Lab Invest. 2015;75(7):549–561. doi: 10.3109/00365513.2015.1057898.
    1. Knip M, Åkerblom HK, Al Taji E, et al. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial. JAMA. 2018;319(1):38–48. doi: 10.1001/jama.2017.19826.
    1. Sassi F, Tamone C, DʼAmelio P. Vitamin D: nutrient, hormone, and immunomodulator. Nutrients. 2018;10(11):1656. doi: 10.3390/nu10111656.
    1. Barbáchano A, Fernández-Barral A, Ferrer-Mayorga G, Costales-Carrera A, Larriba MJ, Muñoz A. The endocrine vitamin D system in the gut. Mol Cell Endocrinol. 2017;453:79–87. doi: 10.1016/j.mce.2016.11.028.
    1. Bashir M, Prietl B, Tauschmann M, et al. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract. Eur J Nutr. 2016;55(4):1479–1489. doi: 10.1007/s00394-015-0966-2.
    1. Knip M, Honkanen J. Modulation of type 1 diabetes risk by the intestinal microbiome. Curr Diab Rep. 2017;17(11):105. doi: 10.1007/s11892-017-0933-9.
    1. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2(1):76–89. doi: 10.1016/S2213-8587(13)70165-7.
    1. Mäkinen M, Simell V, Mykkänen J et al (2014) An increase in serum 25-hydroxyvitamin D concentrations preceded a plateau in type 1 diabetes incidence in Finnish children. 99(11):E2353–E2356

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit